Related Experiment Videos
Melatonin reduces dinitrobenzene sulfonic acid-induced colitis
S Cuzzocrea1, E Mazzon, I Serraino
1Institute of Pharmacology, School of Medicine, University of Messina, Italy. salvator@www.unime.it
Journal of Pineal Research
|February 13, 2001
Summary
Melatonin treatment significantly reduced symptoms and colonic damage in rats with experimental inflammatory bowel disease (IBD). This study suggests melatonin may be a beneficial therapeutic agent for IBD.
Area of Science:
- Gastroenterology
- Pharmacology
- Cellular Biology
Background:
- Inflammatory bowel disease (IBD) involves oxidative stress, inflammation, and increased ICAM-1 expression in the colon.
- Experimental colitis models mimic IBD pathologies, including diarrhea and weight loss.
Purpose of the Study:
- To investigate the therapeutic effects of melatonin on experimental colitis in rats.
- To assess melatonin's impact on oxidative stress, inflammation, and specific molecular markers in the colon.
Main Methods:
- Colitis was induced in rats using dinitrobenzene sulfonic acid (DNBS).
- Melatonin (15 mg/kg) was administered intraperitoneally daily.
- Evaluated parameters included body weight, diarrhea, colonic architecture, myeloperoxidase (MPO) activity, malondialdehyde (MDA) levels, and expression of ICAM-1, P-selectin, nitrotyrosine, PARS, COX-2, and iNOS.
Main Results:
- Melatonin treatment ameliorated diarrhea, weight loss, and colonic tissue damage.
- Melatonin significantly reduced MPO activity, MDA levels, and nitrotyrosine/PARS immunoreactivity.
- Melatonin decreased ICAM-1 and P-selectin expression, and reduced COX-2 and iNOS staining in inflamed colons.
Conclusions:
- Melatonin administration demonstrated significant protective effects against DNBS-induced colitis in rats.
- Melatonin's anti-inflammatory and antioxidant properties suggest its potential as a therapeutic agent for IBD.